On May 21 2026, Eli Lilly and Company announced topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial of retatrutide — an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors. The trial met its primary endpoint, and the reported mean weight-loss numbers are the largest published for any investigational obesity pharmacotherapy to date.
This post breaks down what the topline numbers mean, how they compare to other Phase 3 incretin trials, what the 4 mg low-dose result might imply for tolerability, and what is still unknown until the full dataset is presented at the American Diabetes Association (ADA) 2026 Scientific Sessions in June.
Important disclaimers up front:
- Retatrutide is not approved by the FDA or any regulatory agency. It is available only through clinical trial participation. Compounded retatrutide is not legal under FDA rules.
- These numbers come from a company press release. Full peer-reviewed data — including safety, subgroup analyses, and adverse-event detail — is expected at ADA 2026 in June.
- This post is informational. It is not medical advice and is not a recommendation to use or seek retatrutide.
What TRIUMPH-1 Reported
Lilly's press release reported the following primary topline numbers:
- 28.3% mean body weight loss at 12 mg over 80 weeks — approximately 70.3 lbs of absolute mean weight loss.
- 30.3% mean weight loss at 104 weeks in the BMI ≥35 subgroup (extended follow-up arm).
- Approximately 19% mean weight loss at the 4 mg low-dose arm — approximately 47.2 lbs of absolute mean weight loss. This is the first published data on a 4 mg maintenance dose.
The primary endpoint was met. Lilly indicated that full results, including subgroup analyses and adverse-event data, are expected at ADA 2026. As of the press release, no fatal or unexpected serious safety signals had been disclosed.
How TRIUMPH-1 Compares to SURMOUNT-1 and STEP 1
The three published Phase 3 obesity trials for incretin-based therapies — STEP 1 (semaglutide), SURMOUNT-1 (tirzepatide), and now TRIUMPH-1 (retatrutide) — used different doses, populations, and durations, so direct head-to-head comparison must be interpreted with caution. The reported mean weight-loss numbers, however, are roughly:
- Semaglutide 2.4 mg, 68 weeks (STEP 1): ≈14.9% mean weight loss.
- Tirzepatide 15 mg, 72 weeks (SURMOUNT-1): ≈22.5% mean weight loss.
- Retatrutide 12 mg, 80 weeks (TRIUMPH-1): 28.3% mean weight loss.
- Retatrutide 4 mg, 80 weeks (TRIUMPH-1): ≈19% mean weight loss.
For more detail on the SURMOUNT-1 vs TRIUMPH-1 comparison, see our retatrutide vs tirzepatide comparison. For semaglutide, see semaglutide.
The trend across receptor pharmacology is consistent with the hypothesis that adding receptors expands the mechanism. GLP-1 monotherapy (semaglutide) produces meaningful mean weight loss. Adding GIP (tirzepatide) increases mean weight loss. Adding glucagon receptor agonism (retatrutide) — which increases energy expenditure rather than further suppressing appetite — appears to add another increment.
Why the 4 mg Result Matters
The Phase 2 trial of retatrutide (Jastreboff et al., NEJM 2023) used 4 mg, 8 mg, and 12 mg maintenance doses. The 12 mg dose produced the largest weight loss but also the highest discontinuation rate (16.2%) due to gastrointestinal side effects. Phase 3 TRIUMPH-1 added a maintenance dose tier not previously tested in Phase 2 — the 4 mg low-dose arm.
The reported ≈19% mean weight loss at 4 mg is notable for two reasons:
- It approaches the magnitude reported for tirzepatide's 15 mg arm in SURMOUNT-1 (≈22.5%) — a result achieved at a substantially lower incretin dose intensity.
- It may suggest a clinically usable tolerability-friendly dose tier. If full TRIUMPH-1 data confirms a more favorable gastrointestinal side-effect profile at 4 mg without sacrificing too much efficacy, that has direct implications for individuals who cannot escalate to 12 mg.
This remains a hypothesis pending the full dataset. The 4 mg adverse-event profile, discontinuation rate, and adherence have not yet been reported.
What the BMI ≥35 / 104-Week Subgroup Tells Us
The 30.3% mean weight loss at 104 weeks in the BMI ≥35 subgroup is the largest mean magnitude reported to date. It is from a higher-BMI subgroup with longer follow-up, so direct comparison with the 80-week / general-population 28.3% number is not appropriate. Both findings, however, are consistent with the same general pattern:
- Higher baseline BMI typically produces larger absolute weight loss with incretin therapy.
- Longer trial duration captures more of the steady-state weight loss before plateau effects fully manifest.
- The 104-week data point provides early evidence that retatrutide's weight loss may not plateau as sharply as it has with earlier-generation GLP-1 agonists. This needs to be confirmed in the full dataset and in maintenance-phase analyses.
What's Still Unknown
The press release provided the primary topline efficacy numbers but did not provide:
- Full adverse-event profile: Rates of nausea, vomiting, diarrhea, lipase/amylase elevations, heart-rate changes, and other adverse events by dose arm.
- Discontinuation rates by dose: Critical for the 4 mg tolerability hypothesis.
- Lean mass loss: A consistent concern with all incretin-based obesity therapies. See our companion guide on protein and muscle preservation on GLP-1s.
- Cardiovascular outcomes: Lipid, blood pressure, and HbA1c changes by dose; cardiovascular event data; serious adverse cardiac events.
- Patient-reported outcomes: Quality of life, functional status, and treatment satisfaction.
- Subgroup analyses: Diabetes status, sex, age, and prior incretin use.
- Time-to-effect curves: When weight loss began, when it plateaued, and what proportion of participants reached specific weight-loss thresholds (≥5%, ≥10%, ≥15%, ≥20%, ≥25%).
These details are expected at the ADA 2026 Scientific Sessions in June. Peer-reviewed publication typically follows the conference presentation by several months.
What Happens Next
With the TRIUMPH-1 primary endpoint met, the regulatory timeline is now more concrete:
- June 2026: Full TRIUMPH-1 data expected at the ADA Scientific Sessions in Chicago.
- Late 2026 / 2027: Lilly is expected to file a New Drug Application (NDA) with the FDA following the complete Phase 3 readout. FDA review under priority designation is typically 6–12 months.
- 2027 (at the earliest): Potential FDA approval and commercial availability. Insurance coverage and pricing would follow.
Until then, retatrutide remains investigational. It is not legally available outside of clinical trial enrollment, regardless of any vendor or telehealth claim. Compounded retatrutide is not legal — retatrutide is a proprietary large-molecule biologic, not a simple peptide that compounding pharmacies can legally produce, and FDA rules do not permit compounding of unapproved drugs.
How This Fits the Broader Phase 3 GLP-1 Pipeline
TRIUMPH-1 is part of a wave of pivotal Phase 3 incretin readouts in 2026. Other recent topline announcements include:
- Petrelintide — Roche/Zealand amylin analog, Phase 2 reported 10.7% mean weight loss at 42 weeks; Phase 3 launching H2 2026.
- Survodutide — Boehringer GLP-1/glucagon dual agonist; SYNCHRONIZE-1 reported 16.6% mean weight loss at 76 weeks.
- Eloralintide — Lilly selective AMY1R agonist; Phase 2 reported up to 20.1% mean weight loss at 9 mg over 48 weeks.
- Amycretin — Novo Nordisk oral GLP-1/amylin dual agonist; Phase 2 reported ≈22% subcutaneous / 10.4% oral at 12 weeks.
For an overview of the broader pipeline, see our guide on next-generation GLP-1 peptides in development.
For Readers Currently on a GLP-1 or Considering One
This post is not medical advice. Treatment decisions about GLP-1, dual-agonist, or triple-agonist therapy belong with a qualified clinician who knows your full medical history.
If you want to learn how to track your own response to any incretin-based therapy — biomarkers worth measuring, common confounders, and what signals warrant a clinician conversation — see the Prova guide to body recomposition on GLP-1 drugs and the PeptideWise protein and muscle preservation guide.
This article will be updated when full TRIUMPH-1 data is presented at ADA 2026 in June.